Gene Therapy for Neurodegenerative Diseases
Open accessAbstract
Gene therapy has the potential to provide therapeutic benefit to millions of people with neurodegenerative diseases through several means, including direct correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. Therapeutic efficacy is therefore dependent on knowledge of the disease pathogenesis and the required temporal and spatial specificity of gene expression. An additional critical challenge is achieving the most complete transduction of the target structure while avoiding leakage into neighboring regions or perivascular spaces. The gene therapy field has recently entered a new technological era, in which interventional MRI-guided convection-enhanced delivery (iMRI-CED) is the gold standard for verifying accurate vector delivery in real time. The availability of this advanced neurosurgical technique may accelerate the translation of the promising preclinical therapeutics under development for neurodegenerative disorders, including Parkinson's, Huntington's, and Alzheimer's diseases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Technologies have advanced to facilitate trials of gene therapy in AD.
“Technologies have advanced to facilitate trials of gene therapy in AD and trials are anticipated in the pipeline. 35”
From Alzheimer’s disease drug development pipeline: 2021 (2021) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · see citing works
Adams, J., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W. Y., Goldenthal, S. B., Biglan, K., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,190 · see citing works
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055 · see citing works
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,751 · see citing works
Convection-enhanced delivery of macromolecules in the brain.
Bobo, R. H., Laske, D. W., Akbaşak, A., Morrison, P. F., Dedrick, R. L., & Oldfield, E. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2076 · Cited by 1,414 · see citing works
Argonaute proteins: key players in RNA silencing
Hutvágner, G., & Simard, M. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2321 · Cited by 1,362 · see citing works
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290 · see citing works
Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J. L., Chen, E., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,244 · see citing works
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,068 · see citing works
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067 · see citing works
Lang, A. E., Gill, S., Patel, N., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G. R., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 987 · see citing works
Saudou, F., & Humbert, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.003 · Cited by 945 · see citing works
Marks, W. J., Bartus, R. T., Siffert, J. O., Davis, C. S., Lozano, A. M., Boulis, N. M., Vitek, J. L., Stacy, M. A., Turner, D. A., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 685 · see citing works
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681 · see citing works
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596 · see citing works
Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R. J., & Young, B. A. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 474 · see citing works
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 452 · see citing works
Safety and tolerability of putaminal <i>AADC</i> gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445 · see citing works
Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W. J., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F., & Harvey-White, J. D. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7408 · Cited by 406 · see citing works
Results from a phase I safety trial of <i>hAADC</i> gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370 · see citing works
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344 · see citing works
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P. A., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 297 · see citing works
Olanow, C. W., Bartus, R. T., Baumann, T. L., Factor, S. A., Boulis, N. M., Stacy, M. A., Turner, D. A., Marks, W. J., Larson, P., Starr, P. A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24436 · Cited by 287 · see citing works
Long-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC
Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sánchez‐Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W. C., Reutter, B. W., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.005 · Cited by 282 · see citing works
Point source concentration of GDNF may explain failure of phase II clinical trial
Salvatore, M. F., Ai, Y., FISCHER, B., ZHANG, A., Grondin, R., Zhang, Z., Gerhardt, G. A., & Gash, D. M. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.07.015 · Cited by 261 · see citing works
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 251 · see citing works
McBride, J. L., Pitzer, M. R., Boudreau, R. L., Dufour, B., Hobbs, T., Ojeda, S. R., & Davidson, B. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.219 · Cited by 247 · see citing works
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents
Krauze, M. T., Saito, R., Noble, C. O., Tamas, M., Bringas, J., Park, J. W., Berger, M. S., & Bankiewicz, K. S. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.103.5.0923 · Cited by 235 · see citing works
Rafii, M. S., Tuszynski, M. H., Thomas, R. G., Barba, D., Brewer, J. B., Rissman, R. A., Siffert, J., Aisen, P. S., & for the AAV2-NGF Study Team (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0233 · Cited by 219 · see citing works
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Bartus, R. T., Baumann, T. L., Siffert, J. O., Herzog, C. D., Alterman, R. L., Boulis, N. M., Turner, D. A., Stacy, M. A., Lang, A. E., Lozano, A. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182904faa · Cited by 216 · see citing works
Kordower, J. H., Winn, S. R., Liu, Y. T., Mufson, E. J., Sladek, J. R., Hammang, J. P., Baetge, E. E., & Emerich, D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10898 · Cited by 193 · see citing works
Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms
Levy, R. (2001) · Brain · doi:10.1093/brain/124.10.2105 · Cited by 191 · see citing works
Koliatsos, V., Nauta, H. J. W., Clatterbuck, R. E., Holtzman, D. M., Mobley, W. C., & Price, D. (1990) · Journal of Neuroscience · doi:10.1523/jneurosci.10-12-03801.1990 · Cited by 171 · see citing works
Evers, M. M., Miniarikova, J., Juhas, S., Vallès, A., Bohuslavova, B., Juhasova, J., Skalnikova, H. K., Vodicka, P., Valekova, I., Brouwers, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.021 · Cited by 168 · see citing works
Tuszynski, M. H., Roberts, J. A., Senut, M., U, H. S., & Gage, F. H. (1996) · PubMed · Cited by 164 · see citing works
Ostrem, J. L., Ziman, N., Galifianakis, N. B., Starr, P. A., Luciano, M. S., Katz, M., Racine, C. A., Martin, A. J., Markun, L. C., & Larson, P. (2015) · Journal of neurosurgery · doi:10.3171/2015.4.jns15173 · Cited by 161 · see citing works
Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADC
Hadaczek, P., Eberling, J. L., Pivirotto, P., Bringas, J., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.106 · Cited by 158 · see citing works
Axonal transport of adeno-associated viral vectors is serotype-dependent
Salegio, E. A., Samaranch, L., Kells, A. P., Mittermeyer, G., San Sebastian, W., Zhou, S., Beyer, J., Forsayeth, J., & Bankiewicz, K. S. (2013) · Gene Therapy · doi:10.1038/gt.2012.27 · Cited by 156 · see citing works
Samaranch, L., Salegio, E. A., Sebastián, W. S., Kells, A. P., Bringas, J. R., Forsayeth, J., & Bankiewicz, K. S. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.005 · Cited by 155 · see citing works
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Grondin, R., Kaytor, M. D., Ai, Y., Nelson, P. T., Thakker, D. R., Heisel, J., Weatherspoon, M. R., Blum, J. L., Burright, E. N., Zhang, Z., et al. (2012) · Brain · doi:10.1093/brain/awr333 · Cited by 153 · see citing works
Richardson, R. M., Kells, A. P., Rosenbluth, K. H., Salegio, E. A., Fiandaca, M. S., Larson, P., Starr, P. A., Martin, A. J., Lonser, R. R., Federoff, H. J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.11 · Cited by 145 · see citing works
Self-citationEfficient gene therapy-based method for the delivery of therapeutics to primate cortex
Kells, A. P., Hadaczek, P., Yin, D., Bringas, J., Varenika, V., Forsayeth, J., & Bankiewicz, K. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810682106 · Cited by 134 · see citing works
Emborg, M. E., Carbon, M., Holden, J. E., During, M. J., Ma, Y., Tang, C., Moirano, J. M., Fitzsimons, H. L., Roitberg, B. Z., Tüccar, E., et al. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600364 · Cited by 134 · see citing works
Kells, A. P., Eberling, J. L., Su, X., Pivirotto, P., Bringas, J., Hadaczek, P., Narrow, W. C., Bowers, W. J., Federoff, H. J., Forsayeth, J., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0942-10.2010 · Cited by 133 · see citing works
Miniarikova, J., Zanella, I., Huseinovic, A., van der Zon, T., Hanemaaijer, E. S., Martier, R., Koornneef, A., Southwell, A. L., Hayden, M. R., van Deventer, S. J. H., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.7 · Cited by 129 · see citing works
An Optimized System for Interventional Magnetic Resonance Imaging-Guided Stereotactic Surgery
Larson, P., Starr, P. A., Bates, G., Tansey, L., Richardson, R. M., & Martin, A. J. (2011) · Operative Neurosurgery · doi:10.1227/neu.0b013e31822f4a91 · Cited by 127 · see citing works
Self-citationSu, X., Kells, A. P., Huang, E. J., Lee, H. S., Hadaczek, P., Beyer, J., Bringas, J., Pivirotto, P., Penticuff, J., Eberling, J. L., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.103 · Cited by 112 · see citing works
Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery
Varenika, V., Dickinson, P. J., Bringas, J., LeCouteur, R. A., Higgins, R., Park, J. B., Fiandaca, M. S., Berger, M. S., Sampson, J. H., & Bankiewicz, K. S. (2008) · Journal of neurosurgery · doi:10.3171/jns/2008/109/11/0874 · Cited by 110 · see citing works
Miniarikova, J., Zimmer, V., Martier, R., Brouwers, C. C., Pythoud, C., Richetin, K., Rey, M. J., Lubelski, J., Evers, M. M., van Deventer, S. J. H., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.71 · Cited by 105 · see citing works
A Dose-Ranging Study of AAV-hAADC Therapy in Parkinsonian Monkeys
Forsayeth, J., Eberling, J. L., Sanftner, L. M., Zhen, Z., Pivirotto, P., Bringas, J., Cunningham, J., & Bankiewicz, K. S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.008 · Cited by 103 · see citing works
Richardson, R. M., Kells, A. P., Martin, A. J., Larson, P., Starr, P. A., Piferi, P., Bates, G., Tansey, L., Rosenbluth, K. H., Bringas, J. R., et al. (2011) · Stereotactic and Functional Neurosurgery · doi:10.1159/000323544 · Cited by 102 · see citing works
Self-citationJohnston, L. C., Eberling, J. L., Pivirotto, P., Hadaczek, P., Federoff, H. J., Forsayeth, J., & Bankiewicz, K. S. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.137 · Cited by 88 · see citing works
Cik, M., Masure, S., Lesage, A., van der Linden, I., Gompel, P. V. V., Pangalos, M., Gordon, R., & Leysen, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000306200 · Cited by 82 · see citing works
Anterograde Axonal Transport of AAV2-GDNF in Rat Basal Ganglia
Ciesielska, A., Mittermeyer, G., Hadaczek, P., Kells, A. P., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.248 · Cited by 82 · see citing works
Su, X., Kells, A. P., Salegio, E. A., Richardson, R. M., Hadaczek, P., Beyer, J., Bringas, J., Pivirotto, P., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.114 · Cited by 82 · see citing works
Self-citationSamaranch, L., Blits, B., Sebastián, W. S., Hadaczek, P., Bringas, J., Sudhakar, V. R., Macayan, M., Pivirotto, P., Petry, H., & Bankiewicz, K. S. (2017) · Gene Therapy · doi:10.1038/gt.2017.14 · Cited by 80 · see citing works
Self-citationValles, F. E., Fiandaca, M. S., Eberling, J. L., Starr, P. A., Larson, P., Christine, C. W., Forsayeth, J., Richardson, R. M., Su, X., Aminoff, M. J., et al. (2010) · Neurosurgery · doi:10.1227/neu.0b013e3181f53a5c · Cited by 71 · see citing works
Self-citationGene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease
Dass, B., Olanow, C., & Kordower, J. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s89 · Cited by 67 · see citing works
Yin, D., Valles, F. E., Fiandaca, M. S., Bringas, J., Gimenez, F., Berger, M. S., Forsayeth, J., & Bankiewicz, K. S. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.08.069 · Cited by 66 · see citing works
Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain
San Sebastian, W., Samaranch, L., Heller, G., Kells, A. P., Bringas, J., Pivirotto, P., Forsayeth, J., & Bankiewicz, K. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.48 · Cited by 62 · see citing works
Deep Brain Stimulation in Area LC Controllably Triggers Auditory Phantom Percepts
Larson, P., & Cheung, S. W. (2011) · Neurosurgery · doi:10.1227/neu.0b013e3182320ab5 · Cited by 59 · see citing works
Axonal transport of AAV9 in nonhuman primate brain
Green, F., Samaranch, L., Zhang, H. S., Manning-Bog, A., Meyer, K., Forsayeth, J., & Bankiewicz, K. S. (2016) · Gene Therapy · doi:10.1038/gt.2016.24 · Cited by 57 · see citing works
Lee, P. S., Weiner, G. M., Corson, D. M., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00241 · Cited by 50 · see citing works
Yin, D., Richardson, R. M., Fiandaca, M. S., Bringas, J., Forsayeth, J., Berger, M. S., & Bankiewicz, K. S. (2010) · Journal of neurosurgery · doi:10.3171/2010.2.jns091744 · Cited by 49 · see citing works
Self-citationSan Sebastian, W., Richardson, R. M., Kells, A. P., Lamarre, C., Bringas, J., Pivirotto, P., Salegio, E. A., DeArmond, S. J., Forsayeth, J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.162 · Cited by 48 · see citing works
Self-citationSidiropoulos, C., Rammo, R. A., Merker, B. M., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8125-0 · Cited by 45 · see citing works
ANATOMIC COMPRESSION CAUSED BY HIGH-VOLUME CONVECTION-ENHANCED DELIVERY TO THE BRAIN
Valles, F. E., Fiandaca, M. S., Bringas, J., Dickinson, P. J., LeCouteur, R. A., Higgins, R., Berger, M. S., Forsayeth, J., & Bankiewicz, K. S. (2009) · Neurosurgery · doi:10.1227/01.neu.0000350229.77462.2f · Cited by 34 · see citing works
Controlled dissemination of AAV vectors in the primate brain
Varenika, V., Kells, A. P., Valles, F., Hadaczek, P., Forsayeth, J., & Bankiewicz, K. S. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17511-8 · Cited by 33 · see citing works
Future Applications: Gene Therapy
Richardson, R. M., Varenika, V., Forsayeth, J., & Bankiewicz, K. S. (2009) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2009.04.004 · Cited by 25 · see citing works
Self-citationDrug Delivery for Movement Disorders
Barua, N. U., & Gill, S. S. (2018) · Progress in neurological surgery · doi:10.1159/000481108 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Alzheimer’s disease drug development pipeline: 2021
Cummings, J., Lee, G., Zhong, K., Fonseca, J., & Taghva, K. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12179 · Cited by 539 · see citing works
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131 · see citing works
Christine, C. W., Richardson, R. M., Van Laar, A. D., Thompson, M. E., Fine, E. M., Khwaja, O. S., Li, C., Liang, G. S., Meier, A., Roberts, E. W., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000012952 · Cited by 89 · see citing works
Self-citationThe concept of gene therapy for glaucoma: the dream that has not come true yet
Sulak, R., Liu, X., & Smedowski, A. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.375319 · Cited by 40 · see citing works
Rouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20 · see citing works
- Authors
- Sudhakar, V., & Richardson, R. M.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Richardson, R. Mark
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 16
- Issue
- 1
- Pages
- 166-175
- ISSN
- 1878-7479 (ISSN-L)
- PMC
- PMC6361055
- OpenAlex
- W2904612066
- Cited by
- 212
- References
- 70
- Citations by year
- 2026: 14 · 2025: 35 · 2024: 55 · 2023: 32 · 2022: 31 · 2021: 25 · 2020: 13 · 2019: 6
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neurotherapeutics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- gene therapy, neurodegenerative diseases, convection-enhanced delivery, neuroprotection, neurorestoration, Parkinson's disease, Huntington's disease, Alzheimer's disease, pathogenesis
- MeSH terms
- Animals, Humans, Genetic Therapy, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
